Genfit SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Genfit SA Raises Over EUR 14 Million via Capital Increase
Genfit SA announced that it has raised EUR 14,325,000.72 in the frame of a capital increase of an nominal amount of EUR 732,362.00 through a private placement of new shares to French and Foreign qualified investors via an accelerated bookbuilding procedure. The Company issued 2,929,448 new shares, at a price of EUR 4.89 per share, representing a 19.7% discount based on the volume-weighted average price of five trading days during the period between March 25, 2013 and April 2, 2013 (which is equivalent to a discount of 20% on the average price of the last 20 closing prices). This issue represents 14.43% of the outstanding number of shares and will bring the total number of shares after the issue to 20,299,516. Following their issuance, the new shares will be admitted to trading on NYSE Alternext Euronext which is expected to take place on April 22, 2013. An additional capital increase of EUR 2 million to EUR 5 million (share premium included) with preferential subscription rights will be proposed for a vote by a forthcoming combined Shareholders' Meeting to be convened. Similar discount terms will be proposed.
Latest Key Developments in Biotechnology
- PDL BioPharma Inc gives Q1 2014 revenue guidance in line with analysts' estimates
- Codexis Inc gives FY 2014 revenue guidance
- OXiGENE Inc announces positive topline results from randomized phase 2 study GOG186I of Zybrestat in combination with Avastin for recurrent ovarian cancer
- Applied Nanotech Holdings, Inc and Nanofilm, Ltd. sign merger agreement
- Share this
- Digg this